Novartis Corporation - NVS Earnings per share for the last 12 months

Public company logo of Novartis Inc. (NVS)

Novartis AG (NVS) earns revenue through a diverse portfolio of drugs and fundamental healthcare needs. The strategic exit from the generics segment solidified the company's dominance in high-margin, high-tech therapy. An environmental focus and trial ethics are complemented by the annual change in net income per share over a rolling period, where the -28.70 metric determines the status of the business profitability parameter.

NVS Novartis Corporation: Earnings per share for the last twelve months in the range 02/11/2024 - 11/17/2026

NVS (Novartis): analytical breakdowns and indicator data

- share price and expert price forecast:
Initial company analysis:NVS, Novartis Inc.
Signature product of novartis.com

Year-over-year EPS growth (TTM) measures the rolling growth rate of net income per share, smoothing out gaps between quarterly reports. The 12-month EPS growth trend, with a current value of -28.70, determines the vector of the asset's fundamental reliability. This model is sensitive to peak values, which may signal that the stock is overbought. For Novartis AG (NVS), the Swiss jurisdiction and its status as a manufacturer of critical drugs minimize geopolitical risks, stabilizing this metric.